Chargement en cours...
Through the open door: Preferential binding of dasatinib to the active form of BCR‐ABL unveiled by in silico experiments
Dasatinib is a second‐generation BCR‐ABL inhibitor approved for the treatment of patients with chronic myeloid leukemia, both in the frontline and in the imatinib‐resistant/intolerant settings. The high affinity of dasatinib for the protein is currently assumed to result from its ability to bind bot...
Enregistré dans:
| Publié dans: | Mol Oncol |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5528448/ https://ncbi.nlm.nih.gov/pubmed/23816609 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2013.06.001 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|